Tripep AB (publ.)—Interim Report—January - June 2006

• The company had no net sales in the period. • Research and development costs for the first half-year 2006 amounted to SEK 6.8 million (4.5 m). • The results of the double-blind trial on alphaHGA indicated no significant reduction of patient HIV levels in serum, which consequently led to a complete write-down of all capitalised expenditure on the alphaHGA project as of 31 March 2006, which affected the results negatively by SEK 35.0 m. • The loss after tax for the first half-year 2006 was SEK -53.7 million (-11.0 m). • Earnings per share for the first half-year 2006 were SEK -2.39 (-0.66). • ChronVac-C®: o Convincing results from experimental trials on mice published by Professor Sällberg in June at a conference in Dublin. o Work on toxicology trials continuing according to plan, with the completion of the application for clinical trials underway. Events after the end of the period: • As of 1 July 2006 all existing operations were transferred to the recently formed subsidiary, Tripep Holding AB. • Tripep AB has agreed to acquire residential property and spinning off existing operations to current shareholders, pursuant to the approval of EGM. For more information, please contact Rolf L. Nordström, Chairman of the Board Tel: +44 20 7495 1480, mobile phone: +44 7776 137 400 e-mail: rolf.l.nordstrom@btinternet.com Jan Nilsson, Chief Executive Officer Tel: +46 (0)8 449 8482, mobile: +46 (0)70 466 3163 e-mail: jan.nilsson@tripep.se Anders Vahlne, Head of Research Tel: +46 (0)8 585 81313, mobile: +46 (0)70 928 0528 e-mail: anders.vahlne@ki.se